



29 SEPT – 2 OCT 2022
ICC BELFAST
NORTHERN IRELAND, UK

PROGRAMME

DAY 1 Thursday 29 September		Hall 1A
0900 - 1600	Registration Bag drop Register early: RSV2022 delegates are welcome to join OPTIONS XI DAY 4 sessions at the ICC	
1515 - 1600	Poster Setup	
1700 - 1710	Welcome Address: Chair, Prof. Ultan F. Power Queen's University Belfast	
1710 - 1730	Opening Keynote Early Career Investigator Award Title – tbc Dr Vahid Salimi Tehran University of Medical Sciences, Iran	
1730 - 1900	SESSION 1 – RSV Molecular Biology	
1730 - 1800	Keynote: Structure and Assembly of RSV Prof. David Bhella University of Glasgow, UK	
1800 - 1815	RSV Viral Factories are Druggable Multiphasic Biocondensates Marie-Ann Rameix-Welti Université Paris-Saclay, Université de Versailles, France [ARNI0003]	
1815 - 1830	Elucidating the Role of the Pep27 Fragment in RSV Fusion Protein Function and Stability Hadley Neal University of Kentucky, USA [ARNI0119]	
1830 - 1845	Respiratory Syncytial Virus NS1 Protein Targets the Transactivator Binding Domain of MED25. Monika Bajorek INRAE, France [ARNI0009]	
1845 - 1900	Single-molecule Imaging Unravels Real-time Transcription and Replication Dynamics of RSV Dhanushika Ratnayake Hubrecht Institute, Utrecht, Netherlands [ARNI0136]	
1900 - late	Welcome Reception	
		End of Day 1

DAY 2 **Friday 30 September****Hall 1A****0900 - 1030** **SESSION 2 – RSV Immunology – Pre-Clinical**

0900 - 0930 **Keynote: A Novel Microbiota-host Interaction to Explain How Poor Maternal Diet Predisposes to Severe Viral Bronchiolitis**
A/Prof. Simon Phipps | QIMR Berghofer, QLD, Australia

0930 - 0945 **Comparing the Cell-specific Innate Immune response to RSV between preterm and term infants**
An Yung Ng | Murdoch Children's Research Institute, Royal Children's Hospital, Australia [ARNI0221]

0945 - 1000 **Presence of Neutrophils in the Lungs Prior to Infection with Respiratory Viruses Influences Disease Severity in Mice**
Amber Owen | Imperial College London, UK [ARNI0127]

1000 - 1015 **Advanced modeling of RSV Infection in Neonatal Lambs**
Sarhad Alnajarr | Lambcure LLC, USA [ARNI0029]

1015 - 1030 **Trans-epithelial migration is essential for neutrophil activation in the airway during RSV infection**
Elisabeth Robinson | UCL Great Ormond Street Institute of Child Health, London, UK [ARNI0150]

1030 - 1100 **Refreshment break - Posters**

1100-1230 **SESSION 3 – RSV Vaccines and Monoclonals**

1100 - 1130 **Keynote: Progress in the Prevention of RSV Disease: a Whirlwind Tour**
Prof. Ruth Karron | Johns Hopkins University, USA

1130 - 1145 **Safety and Immunogenicity of mRNA-1345, an mRNA-Based Vaccine Against RSV in Older Adults through 6 Month Follow-up**
Sonia Stoszek | Moderna, Inc., MA, USA [ARNI0055]

1145 - 1200 **NIRSEVIMAB for the Prevention of RSV: Pooled Efficacy from Phase IIB and Phase III Trials in Preterm and Term Infants**
Eric A.F.Simoës | The Children's Hospital, Aurora, USA [ARNI0139]

1200 - 1215 **Long term (2-year) immunogenicity of a combination Ad26.RSV.preF/RSV preF protein vaccine evaluated in a phase 1/2a study**
Rosemary Bastian Arangassery | Janssen Vaccines and Prevention BV, Netherlands [ARNI0045]

1215 - 1230 **Respiratory Syncytial Virus prefusion F (RSVpreF) vaccination: antibody persistence and revaccination**
Edward Walsh | University of Rochester, NY, USA [ARNI0243]

1230 – 1430	Lunch break Posters Industry Symposium sponsored by Sanofi
1430 - 1600	SESSION 4 – RSV Epidemiology and Disease Burden
1430 – 1500	Keynote: An overview of the global burden of RSV Dr Meredith McMorrow CDC, USA
1500- 1515	Estimates of the National Burden of Respiratory Syncytial Virus in Kenyan Children Aged Under 5 years, 2010-2018 Bryan Nyawanda Kenya Medical Research Institute, Kenya [ARNI0145]
1515 - 1530	Timing of infection with respiratory syncytial virus and risk of childhood asthma Tina Hartert Vanderbilt University Medical Center, TN, USA [ARNI0172]
1530 - 1545	Hospitalization rates and outcomes for RSV-associated hospitalizations in adults aged 18 years and older in the United States during two respiratory seasons, October 2018 - April 2020 Fiona Havers Centers for Disease Control and Prevention, GA, USA [ARNI0099]
1545 - 1600	Early detection and prediction of respiratory syncytial virus (RSV) outbreaks using wastewater surveillance Danielle Allen Queen's University Belfast, UK [ARNI0168]
1600 - 1630	Refreshment break - Posters
1630 - 1650	Late Breaker session
1630 - 1640	PK, SNA, and Efficacy to Prevent RSV MALRI from a Phase 1b/2a Study of Monoclonal Antibody Clesrovimab (MK-1654) in Infants Andrew Lee Merck & Co Inc., USA [ARNI0268]
1640 - 1650	Nirsevimab for the prevention of RSV disease in healthy late-preterm and term infants: follow-up through second RSV season Ron Dagan Ben Gurion University, Beer Sheva Israel [ARNI0273]
1650 - 1800	SESSION 5 – Public Engagement and Question Time
1800 - 2000	Poster Session Wine Reception
End of Day 2	

DAY 3 Saturday 1 October**Hall 1A****0900 - 1030****SESSION 6 – RSV Antivirals and Therapeutics**

0900 – 0930

Keynote: Therapeutic Targeting of the RSV Polymerase Complex
Prof Richard Plemper | Georgia State University, Atlanta, USA

0930 - 0945

A Phase 3 Pivotal Study of Efficacy and Safety of Oral Ziresovir in RSV-Infected Hospitalized Infants

Jim Wu | Shanghai Ark Biopharmaceutical, China

[ARNI0072]

0945 - 1000

EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus

Micheal Rhodin | Enanta Pharmaceuticals, MA, USA

[ARNI0028]

1000 - 1015

Immunomodulation Strategy Against Respiratory Syncytial Virus Infection by Using Lung Primocolonizing Bacteria

Claire Chottin | INRAE, France

[ARNI0242]

1015 - 1030

Repurposing Screen Identifies Ionafarnib as RSV Fusion Protein Inhibitor

Xiaoyu Zhang | Institute for Experimental Virology, Twincore, Hannover, Germany

[ARNI0122]

1030 - 1100

Refreshment break - Posters**1100 - 1230****SESSION 7 – RSV Pathogenesis and Immunity in Humans**

1100 – 1130

Keynote:
Older Age and its Impact on Infection in Adults after Human RSV Challenge
Prof Chris Chiu | Imperial College London, UK

1130 - 1145

Severity-Associated Transcriptional Signatures in the Respiratory Mucosa during Human Paediatric RSV Infection

Megan Barnes | Imperial College London, UK

[ARNI0087]

1145 - 1200

Assessment of Pediatric Lung Respiratory Syncytial Virus Infection at the Single Cell Level

Thomas Mariani | University of Rochester, NY, USA

[ARNI0178]

1200 - 1215

Differential responses of paediatric airway epithelium from wheezers and non-wheezers to RSV and/or aeroallergens

Sheerian Manzoor | Queen's University Belfast, UK

[ARNI0084]

1215 - 1230

Sex-Dependent Enhancement of Respiratory Syncytial Virus Infection by Toll-Like Receptor 7

Ryley McClelland | University of Alberta, Canada

[ARNI0190]

1230 - 1430

Lunch

1300 - 1400	<p>Industry symposium sponsored by GlaxoSmithKline Biologicals SA Gaining clarity: the factors that increase risk of viral respiratory disease in adults</p> <p>1300-1305 Welcome & Introductions – Peter Openshaw Imperial College London, UK 1305-1315 Burden of Respiratory Disease in High-Risk Adult Populations Ann Falsey University of Rochester School of Medicine, New York, USA 1315-1330 Immune Mechanisms Underlying Risk of Infectious Disease in Adults Steven Varga University of Iowa, Iowa City, USA 1330-1345 Respiratory Disease Pathogenesis in Adults Peter Openshaw Imperial College London, UK 1345-1355 Audience Q&A – all speakers 1355-1400 Closing remarks - Peter Openshaw Imperial College London, UK</p>
1430 - 1630	<p>SESSION 8 – RSV Co-infections with Other Viruses and/or Bacteria</p>
1430 - 1500	<p>Keynote: Dr Natasha Halasa Vanderbilt University Medical Center, USA</p>
1500 - 1515	<p>In Vitro Coinfection by Respiratory Syncytial Virus and Influenza A Virus Generates Hybrid Virions with Altered Structure and Tropism Joanne Haney MRC-University of Glasgow Centre for Virus Research, UK [ARNI0248]</p>
1515 - 1530	<p>Streptococcus Pneumoniae Carriage Density and Associated Respiratory Virus Coinfections in a Congregate Shelter Population in King County, WA Julia Rogers University of Washington, USA [ARNI0189]</p>
1530 - 1545	<p>Viral Infections and Co-infections Among American Indian and Alaska Native Children with Acute Respiratory Illness, 2019-2022 Rachel Hartman Johns Hopkins University, USA [ARNI0232]</p>
1545 - 1600	<p>Strong Remodeling of RSV-induced Transcriptional Signature in the Early Stages of Bacterial Superinfection in Human Airway Epithelium Justine Oliva CIRI (Centre International de Recherche en Infectiologie), France [ARNI0135]</p>
1600 - 1630	<p>Refreshment break Posters</p>
1630 - 1730	<p>Chanock Lecture – Prof. Larry Anderson, Emory University, USA RSV Then, Now and Tomorrow, One View</p>
1730 - 1815	<p>Free time</p>
1815 - 1830	<p><i>bus transportation from ICC to Conference Social Event</i></p>
1830 - late	<p>Gala Evening at the Titanic Centre Titanic Centre Tour, Wine Reception & Gala Dinner End of Day 3</p>

0930 - 1100

SESSION 9 – HMPV and Other Respiratory Viruses

0930 - 1000

Human Metapneumovirus Replication and Spread

Keynote: Prof. Rebecca Dutch | University of Kentucky College of Medicine, USA

1000 - 1015

Human metapneumovirus lacking M2-2 protein expression accumulates defective interfering particles and hypermutated genomes that induce type-I interferon production upon infection.

Kevin Groen | Erasmus MC, Netherlands

[ARNI0180]

1015 - 1030

Investigating The Role of HIF-1a in hMPV and RSV Infections

Dorothea Morris | University of Texas Medical Branch, USA

[ARNI0048]

1030 - 1045

Cross-Protective Antibodies Against Common Endemic Respiratory Viruses

Jim Boonyaratanakornkit | Fred Hutchinson Cancer Center, WA, USA

[ARNI0096]

1045 - 1100

Immunocompromised Cotton Rat Model of Human Metapneumovirus (hMPV) Infection

Marina Boukhvalova | Sigmovir Biosystems, Inc., USA

[ARNI0174]

1100 – 1130

Refreshment break | Posters

1130 - 1300

SESSION 10 – Big Data and RSV

1130 - 1200

Using Data to Guide Policy – From Community Transmission to Vaccine Implementation

Keynote: Prof. Cheryl Cohen | University of Witwatersrand & Co-head NICD, S.Africa

1200 - 1215

Examining the Relationship Between Respiratory Syncytial Virus, Influenza, and Rotavirus Seasons' Timing and Severity, and Infant Age at Viral Seasons' Peaks, with Subsequent Childhood Asthma

Michelle Dimitris | Children's Hospital of Eastern Ontario, Canada

[ARNI0056]

1215 - 1230

A large-scale multi-national prospective observational cohort study documenting the summer 2021 RSV epidemic in the United Kingdom and Ireland

Thomas Williams | University of Edinburgh, UK

[ARNI0059]

Machine Learning in asthma: Uncovering the Link with RSV Bronchiolitis

Keynote: Prof. Adnan Custovic | Imperial College London, UK

1300 - 1500

Lunch

<p>1330 - 1430</p>	<p>Industry symposium sponsored by AstraZeneca Understanding the Heritage of RSV Immunoprophylaxis to Inform the Care of Our Vulnerable Patients Prof. Sánchez Luna Paediatrics Dept., Hospital General Universitario 'Gregorio Marañón' & Medical Director Neonatology Division NICU</p> <p>1330-1410 Presentation overview:</p> <ul style="list-style-type: none"> • Current status of RSV infection, epidemiology and unmet needs • Long-term sequelae of early lung insults • Current management guidelines and recommendations for the prevention of RSV infections • The concept of RSV immunoprophylaxis - recommended approach for prevention and treatment of RSV-related clinical outcomes <p>1410-1430</p> <ul style="list-style-type: none"> • Q&A session
<p>1500 - 1630</p>	<p>SESSION 11 – The BIG DEBATE <i>Our rudimentary understanding of RSV pathogenesis in humans remains a major block to developing RSV vaccines and antivirals</i></p>
<p>1630 -></p>	<p>Closing Remarks</p>
<p>End of Day 4</p>	